Renaissance Technologies
RVMD icon

Renaissance Technologies’s Revolution Medicines RVMD Stock Holding History

Renaissance Technologies’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,200
Closed -$603K – 3559
2026
Q1 		$603K Buy
+6,200
New +$626K ﹤0.01% 2522
2025
Q4 		– Sell
-253,104
Closed -$11.8M – 3681
2025
Q3 		$11.8M Buy
253,104
+9,600
+4% +$376K 0.02% 1008
2025
Q2 		$8.96M Buy
243,504
+100,700
+71% +$3.87M 0.01% 1127
2025
Q1 		$5.05M Buy
+142,804
New +$5.8M 0.01% 1426
2023
Q2 		– Sell
-43,300
Closed -$938K – 4218
2023
Q1 		$938K Buy
+43,300
New +$1.07M ﹤0.01% 2521
2022
Q4 		– Sell
-68,900
Closed -$1.36M – 4357
2022
Q3 		$1.36M Buy
+68,900
New +$1.51M ﹤0.01% 2297
2022
Q1 		– Sell
-55,100
Closed -$1.39M – 4403
2021
Q4 		$1.39M Buy
+55,100
New +$1.55M ﹤0.01% 2425
2021
Q3 		– Sell
-22,900
Closed -$727K – 3787
2021
Q2 		$727K Buy
22,900
+13,300
+139% +$464K ﹤0.01% 2806
2021
Q1 		$440K Buy
+9,600
New +$430K ﹤0.01% 2954

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Renaissance Technologies's RVMD Position: Q2 2026 in Review

Renaissance Technologies sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 6,200 shares — an estimated $603K sold.

Renaissance Technologies first reported a position in RVMD in Q1 2021 and held it in 9 quarters. The position peaked at $11.8M in Q3 2025. 688 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Renaissance Technologies reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 6,200 Revolution Medicines shares in Q2 2026, an estimated $603K.
  • Renaissance Technologies first reported a position in Revolution Medicines in Q1 2021 and held it in 9 quarters.
  • Renaissance Technologies's Revolution Medicines position peaked at $11.8M in Q3 2025.
  • 688 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.